产品名称：马来酸桂哌齐特
产品别名：Cinepazide Maleate

生物活性：

Description

Cinepazide Maleate is a vasodilator. Target: Others Cinepazide maleate is a maleate salt form of cinepazide which is a vasodilator. Cinepazide (30 mg/kg, i.v.) potentiated the vertebral vasodilator response of dogs to intravertebral adenosine and cyclic AMP, Intravertebral cinepazide(1-10 mg) increased vertebral blood flow in a dose-related manner and the effect was partially inhibited by intravenous pretreatment with aminophylline but not by pretreatment with autonomic antagonists. Cinepazide resembled cinnarizine and papaverine in that the drug antagonized rabbit aortic contraction induced by KCl, norepinephrine or CaCl2 [1]. Cinepazide in concentrations ranging from 10-6 to 10-5M augmented the relaxing responses to ATP, adenosine and cAMP. However, this agent did not affect the relaxations induced by isoproterenol and papaverine and the contractions induced by 5-HT, prostaglandin F2α and ATP. cinepazide selectively potentiates the relaxing response mediated through purinergic P1 receptors [2].

Solvent&Solubility

In Vitro:

DMSO : 100 mg/mL (187.42 mM; Need ultrasonic)

H_2O : 50 mg/mL (93.71 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	1.8742 mL	9.3708 mL	18.7417 mL
	5 mM	0.3748 mL	1.8742 mL	3.7483 mL
	10 mM	0.1874 mL	0.9371 mL	1.8742 mL

*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。

储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 **In Vitro** 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.请依序添加每种溶剂： 10% DMSO→40% PEG300 →5% Tween-80 → 45% saline

Solubility: ≥ 2.75 mg/mL (5.15 mM); Clear solution

此方案可获得 ≥ 2.75 mg/mL (5.15 mM，饱和度未知) 的澄清溶液。

以 1 mL 工作液为例，取 100 μL 27.5 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入 50 μL Tween-80，混合均匀；然后继续加入 450 μL 生理盐水定容至 1 mL。

2.请依序添加每种溶剂： 10% DMSO→ 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.75 mg/mL (5.15 mM); Clear solution

此方案可获得 ≥ 2.75 mg/mL (5.15 mM，饱和度未知) 的澄清溶液。

以 1 mL 工作液为例，取 100 μL 27.5 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

	3.请依序添加每种溶剂： 10% DMSO →90% corn oil Solubility: ≥ 2.75 mg/mL (5.15 mM); Clear solution 此方案可获得 ≥ 2.75 mg/mL (5.15 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例，取 100 μL 27.5 mg/mL 的澄清 DMSO 储备液加到 900 μL 玉米油中，混合均匀。
References	[1]. Akashi, A., et al., [Cardiovascular pharmacology of cinepazide, a new cerebral vasodilator (author's transl)]. Nihon Yakurigaku Zasshi, 1979. 75(5): p. 507-16. [2]. Muramatsu, I., et al., Effects of cinepazide on the purinergic responses in the dog cerebral artery. Pharmacology, 1984. 28(1): p. 27-33.